期刊文献+

CALLG2008方案治疗60岁以下初发成人急性B淋巴细胞白血病的临床研究 被引量:2

Efficacy and safety of CALLG2008 protocol in treatment of patients with incipient acute B lymphoblastic leukemia
下载PDF
导出
摘要 目的评价按照中国成人急性淋巴细胞白血病(ALL)协作组制定的成人ALL序贯化疗整体方案(CALLG2008)治疗60岁以下初发成人B细胞ALL(B-ALL)的疗效,并比较分析不同危险因素分层亚组之间的治疗结果,观察异基因造血干细胞移植(Allo-SCT)对患者生存期的影响。方法对2009年3月至2014年8月接受CALLG2008方案治疗的60岁以下初发成人B-ALL患者39例进行随访,分析接受该方案诱导治疗后患者的完全缓解(CR)率、毒性反应和总生存(OS)、无事件生存(EFS)情况。结果39例患者中3例早期死亡,其余36例中33例获CR,1个疗程CR率为91.7%。随访至2014年8月1日,中位随访时间25个月;预计3年OS率为53.7%,EFS率为45.6%。预后因素分析提示,患者年龄>35岁以及初诊时白细胞计数>30×109/L是预后的不良因素。Allo-SCT能显著延长患者尤其是高危组患者的OS期及EFS期。主要不良反应为血液学毒性反应,诱导治疗中有88.9%(32/36)出现Ⅳ级血液学毒性反应。结论 CALLG2008方案治疗60岁以下成人B-ALL有较高CR率及长期生存。患者年龄和初诊时白细胞计数是影响预后的重要因素。Allo-SCT可明显延长OS期。 Objective To evaluate the efficacy and safety of CALLG2008 protocol, which was suggested by China Collaborative Group of Acute Lymphoblastic Leukemia, in patients with incipient acute B lymphoblastic leukemia. Methods The clinical data of 39 patients aged〈60 years with acute B lymphoblastic leukemia (B- ALL) receiving CALLG2008 protocol were reviewed. The event- free survival (EFS) , overal survival (OS) rate and adverse events were assessed. Results Thirty- three (91.7%) patients showed complete remission. Median OS was 25 months. Three years estimated OS and EFS rates were 53.7%and 45.6%, respectively (median fol ow- up, 25 months). Age〉35 years and white blood cel count〉30×109/L at diagnosis were associated with shorter OS and EFS. Al ogeneic hematopoietic stem cel transplantation significantly prolonged the OS and EFS, especial y in patients with high risks. Conclusion These data indicate that CALLG2008 protocol for ALL exhibits benefit in the improvement of outcomes of adult B- ALL patients.
出处 《浙江医学》 CAS 2016年第12期906-910,935,共6页 Zhejiang Medical Journal
基金 浙江省卫生厅科研基金(2012KYA069) 浙江省中医药管理局科研基金(2012ZA073) 浙江省重点科技创新团队(2011R50015)
关键词 急性淋巴细胞白血病 化疗 预后 PH染色体 Acute lymphoblastic leukemia Chemotherapy Prognosis Ph chromosome
  • 相关文献

参考文献15

  • 1Br L ggemann M, G kbuget N, Kneba M. Acute lymphoblastic leukemia: monitoring minimal residual disease as a therapeutic principle[J]. Semin Oncol,2012,39(1 ):47-57.
  • 2Ram R, Wolach O, Vidal L, et al. Adolescents and young adults with acute lymphoblastic leukemia have a better outcome when treated with prdiatic-inspired regimens: systematic review and meta-analysis[J]. Am J Hematol,2012,87(5):472-478.
  • 3DeAngelo D J, Stevenson K E, Dahlberg S E, et al. Long-term outcome of a pediatric-inspired regimen used for adults aged 18-50 years with newly diagnosed acute lymphoblastic leukemia [J]. Leukemia,2015,29(3):526-534.
  • 4杨小珠,刘庭波,郑静,陈步远,陈鑫基,郑晓云,李静,胡建达.CALLG2008方案治疗成人急性淋巴细胞白血病的单中心疗效分析[J].中国实验血液学杂志,2013,21(4):886-890. 被引量:8
  • 5Bassan R, Hoelzer D. Modern therapy of acute lymphoblastic leukemia[J]. J Clin Oncol,2011,29(5):532-543.
  • 6Yeoh A E, Tan D, Li C K, et al. Management of adult and paediatric acute lymphoblastic leukaemia in Asia: resource-stratified guide- lines from the Asian Oncology Summit 2013[J]. Lancet Oncol, 2013, 14(12):e508-523.
  • 7Rowe J M, Buck G, Burnett A K, et al. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1 500 pa- tients from the international ALL trial: MRC UKALL XlI/ECOG E2993[J]. Blood,2005, 106(12):3760-3767.
  • 8Mizuta S, Matsuo K, Nishiwaki S, et al. Pretransplant administration of imatinib for alIo-HSCT in patients with BCR-ABL-positive a- cute lymphoblastic leukemia[J]. Blood,2014,123(15):2325-2332.
  • 9Moorman A V, Harrison C J, Buck G A, et al. Karyotype is an in- dependent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treat- ed on the Medical Research Council (MRC) UKALLXlI/Eastern Cooperative Oncology Group (ECOG) 2993 trial[J]. Blood,2007, 109(8):3189-3197.
  • 10Daver N, Thomas D, Ravandi F, et al. Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-posi- tive acute lymphoblastic leukemia[J]. Haematologica, 2015, 100 (5):653-661.

二级参考文献10

  • 1Anthony H, Goldstore, Susan M, et al. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: Final results of the International ALL trial ( MRC UKALL XII/ECOG E2993 ) . Blood ,2008 ; ( 111 ) : 1827 - 1833.
  • 2Huguet F, Leguay T, Buzyn A, et al. Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study. J Clin Oncol, 2009;(27) :911 -918.
  • 3Brnggemann M, Raft T, Flohr T, et al. Clinical significance of mini- mal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia. Blood ,2006 ; ( 107 ) : 1116 - 1123.
  • 4Bassan R, Spinelli O, Oldani E, et al. Improved risk classification for risk-specific therapy based on the molecular study of minimal re- sidual disease (MRD) in aduh acute lymphoblastic leukemia (ALL). Blood ,2009 ; ( 113 ) :4153 -4162.
  • 5Moorman AV, Chihon L, Bown N,et al. A population-based cytoge- netic study of adults with acute lymphoblastic leukemia. Blood ,2010; 115(2) :206 -214.
  • 6Drexler HG, Thiel E. Review of the incidence and clinical relevance of myeloid antigen-positive acute lymphoblastic leukemia. Leukemia, 1991 ;5(8) :637 -645.
  • 7Unal S, Cetin M. The prognostic impact of myeloid antigen expres- sion in pediatric acute lymphoblastic leukemia patients. Turk J Pedi- atr,2008 ;50(6) :533 -536.
  • 8章红涛,赵芳,马建华,张艳芳.VMCLD方案治疗成人初治急性淋巴细胞白血病疗效观察[J].实用癌症杂志,2011,26(2):194-195. 被引量:2
  • 9秦晓铧,陈立,陈国枢,谢晓玲,黎国伟,许先吟.Hyper-CVAD方案治疗成人急性淋巴细胞白血病疗效分析[J].中国医药科学,2011,1(22):65-65. 被引量:3
  • 10杨崇礼,张晓波.全国白血病发病情况调查[J].中国医学科学院学报,1992,14(1):12-19. 被引量:42

共引文献7

同被引文献13

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部